Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Darolutamide in Castration-Resistant Prostate Cancer Extension Study
NCT01429064Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- Jun 2011
- Primary completion
- Nov 2015
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 2 trial of darolutamide in castration-resistant prostate cancer (CRPC), sponsored by Orion Corporation. Started Jun 2011; status: completed.
02
Drugs
darolutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01429064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01429064.